These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10797269)

  • 21. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
    J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients.
    Palermo B; Campanelli R; Mantovani S; Lantelme E; Manganoni AM; Carella G; Da Prada G; della Cuna GR; Romagne F; Gauthier L; Necker A; Giachino C
    Eur J Immunol; 2001 Feb; 31(2):412-20. PubMed ID: 11180105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
    Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.
    Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P
    J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
    Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
    Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
    Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
    Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.
    Rubio-Godoy V; Dutoit V; Zhao Y; Simon R; Guillaume P; Houghten R; Romero P; Cerottini JC; Pinilla C; Valmori D
    J Immunol; 2002 Nov; 169(10):5696-707. PubMed ID: 12421949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
    Vignard V; Lemercier B; Lim A; Pandolfino MC; Guilloux Y; Khammari A; Rabu C; Echasserieau K; Lang F; Gougeon ML; Dreno B; Jotereau F; Labarriere N
    J Immunol; 2005 Oct; 175(7):4797-805. PubMed ID: 16177129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
    Loftus DJ; Castelli C; Clay TM; Squarcina P; Marincola FM; Nishimura MI; Parmiani G; Appella E; Rivoltini L
    J Exp Med; 1996 Aug; 184(2):647-57. PubMed ID: 8760818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.
    Tsomides TJ; Reilly EB; Eisen HN
    Int Immunol; 1997 Feb; 9(2):327-38. PubMed ID: 9040014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
    Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC
    Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
    Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
    Dunbar PR; Smith CL; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris AL; Cerundolo V
    J Immunol; 2000 Dec; 165(11):6644-52. PubMed ID: 11086110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.
    Blanchet JS; Valmori D; Dufau I; Ayyoub M; Nguyen C; Guillaume P; Monsarrat B; Cerottini JC; Romero P; Gairin JE
    J Immunol; 2001 Nov; 167(10):5852-61. PubMed ID: 11698460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.